Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates
New York, February 3, 2026, 19:37 EST — After-hours update
- Merck shares climbed roughly 2.2% in after-hours trading, following a volatile session on Tuesday
- The drugmaker’s 2026 forecast fell short of Wall Street revenue estimates, weighed down by patent expirations on older drugs
- Investors are eyeing Keytruda’s demand, Gardasil’s setbacks in China, and crucial FDA decision dates ahead
Merck & Co shares climbed 2.2% in after-hours trading Tuesday, closing at $115.84. During the session, the stock fluctuated between $109.02 and $118.35.
This move is significant as Merck heads into 2026 facing a familiar challenge: robust growth in its oncology portfolio paired with a widening gap from aging drugs. The…
